intraperitoneal irinotecan + capecitabine + oxaliplatin

This investigational treatment regimen, developed at Erasmus Medical Center, combines the intraperitoneal (IP) administration of irinotecan with standard systemic chemotherapy (typically CAPOX: capecitabine and oxaliplatin, or FOLFOX: 5-fluorouracil, leucovorin, and oxaliplatin) for the treatment of gastric cancer with peritoneal metastases. Irinotecan is a small molecule topoisomerase I inhibitor that is converted into its active metabolite, SN-38, which is significantly more cytotoxic. By delivering irinotecan directly into the peritoneal cavity via a catheter-based port system, the treatment aims to achieve higher local drug concentrations to better target peritoneal carcinomatosis, which often responds poorly to purely systemic therapy. A Phase I study (NCT05379790) established the safety and maximum tolerated dose of IP irinotecan at 75 mg when combined with systemic CAPOX, leading to a planned Phase II multicenter study to evaluate feasibility and efficacy.

Other names

IP irinotecan + CAPOXIP irinotecan + FOLFOXIntraperitoneal Irinotecan for Gastric Peritoneal Metastaseschemotherapy-Erasmus Medical Center-gastric cancer